CA-CIRCLECI
14.3.2024 14:01:34 CET | Business Wire | Press release
CircleCI, the leading continuous integration and continuous delivery (CI/CD) platform, today unveiled CircleCI releases, which enables developers to automate the release orchestration process directly from the CircleCI UI. With current support for Kubernetes and Amazon SageMaker, developers now have end-to-end visibility of their deployments in production and access to rollback commands (e.g., restore version, scale component, and restart component) for seamless release management. CircleCI releases makes deploying code less risky, user-focused, and more accessible for developers to ship faster with confidence.
Today, developers operate in increasingly complex tech stacks yet are under pressure to move quickly without compromising software quality. As a result, elite engineering teams are incorporating agile development practices like progressive delivery and canary releases, which provide the guardrails necessary for risk-free deployments via the ability to target, segment, and roll back releases. CircleCI releases enables software teams to automate the progressive delivery process with support for Argo Rollouts, giving developers complete control over their releases. Future support for blue-green deployments is slated for later in 2024. By automating CI/CD pipelines directly into the release orchestration process, software teams dramatically reduce mean-time-to-recovery (MTTR), giving them the confidence to resolve issues should releases go awry with little to no impact on their customers.
Key features and benefits of CircleCI releases include:
- Change validation: Developers can validate the entire change from build to production.
- User-focused releases and minimized risk: Developers can connect their CI/CD pipeline directly to the customer experience to make releases user-focused, risk-free, and rollback-friendly.
- Increased code confidence: With automated release orchestration, teams will definitively know that their code is working as intended.
- Automated rollbacks: Manual rollbacks take 45 minutes to an hour. Automated rollbacks make the delivery process fast, efficient, and streamlined.
- Real-time service validation: Developers can safely release code to a controlled subset of real users in a live production environment to get immediate feedback on how code performs. Flexible subsets include internal testers, beta customers, or an external low-risk customer group of choice.
- Performance degradation prevention: Automate your release conditions and best practices into a release policy to act as guardrails. By automating software validation in production and rolling back releases when necessary, developers, operators, and customers are protected from performance degradation.
“If you look at every other deploy and release vendor on the market, they’re built to service centralized release and operations teams who want tighter control over deploys,” said Rob Zuber, CTO of CircleCI. “But this doesn’t reflect the reality of elite software teams who depend on developers to drive and deliver fast innovation. Our approach to CircleCI releases provides a developer-centric workflow that enables them to ship faster and monitor new features in production coupled with the safety net of quickly rolling back releases if something goes wrong.”
CircleCI releases is now available to all CircleCI users. To learn more or chat about how CircleCI can empower your team to deliver innovation faster, visit one of our experts at KubeCon EU, booth M16 from March 19-21, 2024. Get started using CircleCI releases today.
About CircleCI
CircleCI is a leading continuous integration and continuous delivery (CI/CD) platform, enabling more than two million global users on elite engineering teams like Okta, Hinge, and Hugging Face to rapidly build, test, deploy, and monitor software they can trust. Through powerful pipeline automation, CircleCI manages limitless complexity at scale through unmatched flexibility and reliability, reducing the time from build to delivery by 3x the industry average. For more information about CircleCI, visit www.circleci.com or follow us on Twitter, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314509917/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom